0
0
New Delhi, July 19 — In a development that could transform how cancer and certain autoimmune diseases are treated, researchers have identified a gene crucial for absorbing vitamin D, which may also hold the key to destroying cancer cells without harming healthy tissue.
The gene, named SDR42E1, is essential for vitamin D absorption and metabolism in the human body. The discovery, detailed in the journal Frontiers in Endocrinology, indicates that selectively blocking this gene may cripple cancer cell survival while sparing normal cells.
“Our findings show that targeting SDR42E1 may selectively halt cancer growth,” said Dr. Georges Nemer, Professor at the College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar.
A Genetic Vulnerability in Cancer Cells
Previous studies had linked mutations in SDR42E1 — which is located on chromosome 16 — to vitamin D deficiency. Such mutations result in an inactive protein, disrupting the body’s ability to process vitamin D.
Building on these insights, the research team used advanced CRISPR/Cas9 gene-editing tools to alter the SDR42E1 gene in HCT116, a well-known human colorectal cancer cell line. Under normal conditions, these cells show high levels of SDR42E1, hinting at the gene’s importance to their growth and survival.
When the researchers introduced the faulty version of the gene, the cancer cells’ viability plummeted by 53%. This dramatic drop suggests that therapies targeting SDR42E1 could specifically attack cancer cells, letting healthy cells remain unaffected.
“This opens exciting possibilities in precision oncology, although further clinical studies are essential before we can translate it into actual therapies,” noted Dr. Nagham Nafiz Hendi, Professor at Middle East University, Amman, Jordan.
Broader Implications for Disease Treatment
Because SDR42E1 is closely tied to vitamin D metabolism, it could also serve as a target for therapies addressing autoimmune and metabolic disorders where vitamin D plays a central regulatory role.
Still, the research team urges caution. The long-term impact of manipulating SDR42E1 on vitamin D balance in the body remains uncertain.
“We must understand more about how SDR42E1 impacts systemic vitamin D function before moving forward,” Nemer added.
The results mark a promising leap toward personalized medicine and gene-guided treatments, but substantial research and clinical testing are required before such therapies become available to patients.
Disclaimer
This article is based on preliminary scientific findings. The research described represents an exciting advance, but new therapies targeting SDR42E1 are not yet available. Anyone concerned about their health or interested in cancer treatment options should consult a qualified medical professional. This report does not constitute medical advice or guidance.
